MorphoSys AG PE Ratio 2018-2021 | MOR

Current and historical p/e ratio for MorphoSys AG (MOR) from 2018 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. MorphoSys AG PE ratio as of November 29, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

MorphoSys AG PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-11-29 10.06 0.00
2021-09-30 11.76 $-1.32 0.00
2021-06-30 19.25 $-0.93 0.00
2021-03-31 21.80 $-1.56 0.00
2020-12-31 28.34 $0.50 56.68
2020-09-30 31.39 $0.21 149.48
2020-06-30 31.67 $0.58 54.60
2020-03-31 24.57 $0.98 25.07
2019-12-31 35.67 $-0.90 0.00
2019-09-30 27.47 $-0.85 0.00
2019-06-30 24.14 $-0.36 0.00
2019-03-31 22.72 $-0.54 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.357B $0.374B
MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09